ClinicalTrials.gg
CompletedNCT00362115Updated Apr 19, 2011Results posted

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

A Phase 2 interventional study of Azilsartan Medoxomil and Azilsartan Medoxomil in Hypertension, sponsored by Takeda. Completed at 54 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
13th of 21
449 · median 566
Started
2006
the only one that year
Phase 2
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 13th largest by enrollment, is the only one that started in 2006, is the only one in phase 2, and was the 1st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Data from the Framingham Heart study suggest that the lifetime risk of developing hypertension among 55- to 65-year-old individuals is greater than 90%. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of hypertension treatments, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully. To help address these matters, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure proposes a more aggressive intervention to hypertension management with more potent antihypertensive agents and combination therapy.

Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug that is rapidly hydrolyzed to the activity moiety, azilsartan, which is an angiotensin II type 1 receptor antagonist. This study is proposed to evaluate the efficacy, safety and tolerability of multiple doses of azilsartan medoxomil at five dose levels in subjects with mild to moderate uncomplicated essential hypertension.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 11 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations, electrocardiogram Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at approximately 24 and 36 hour intervals.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • blood pressure
  • diastolic blood pressure
  • drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Mild to moderate uncomplicated essential hypertension.
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Must be in good health as determined by a physician.
  4. The subject has clinical laboratory evaluations within the reference range for the testing laboratory unless the results are deemed not by the investigator or sponsor.
  5. The subject is willing to discontinue current antihypertensive medications at Screening Day minus 21.

Exclusion criteria

Exclusion Criteria

  1. Diastolic blood pressure less than 95 or greater than 114 mmHg at Placebo Run-in Day minus 14 or Randomization visit, or systolic blood pressure greater than 180 mm Hg.
  2. Decrease of more than or equal to 8 mm Hg in clinic diastolic blood pressure between Placebo Run-in Day minus 14 and Randomization visit.
  3. Has taken within 7 days prior to placebo run-in, or is expected to take medications known to affect blood pressure and is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
  4. Hypersensitive to angiotensin II receptor blockers.
  5. History of an acute myocardial infarction within 12 months prior to Screening, history of coronary revascularization within 6 months prior to Screening, or any history of heart failure, post-myocardial infarction angina, hypertensive encephalopathy, cerebrovascular accident, or .
  6. cardiac conduction defects (eg, 3rd degree atrioventricular block, left bundle branch block, atrial fibrillation or flutter).
  7. Secondary hypertension of any etiology.
  8. Upper arm circumference less than 24 or greater than 42 cm.
  9. Works night (3rd) shift (defined as 11pm to 7am).
  10. Non-compliant (less than 80%) with study medication during Placebo Run-in period.
  11. Significant, moderate to severe renal dysfunction (confirmed by serum creatinine of greater than 2 mg per dl or disease (including renal artery stenosis or known nephrotic proteinuria).
  12. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
  13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not include those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin).
  14. Type 1 or uncontrolled type 2 diabetes mellitus (confirmed by glycosylated greater than 9.5%).
  15. level of greater than 2.5 times the , active liver disease, or jaundice.
  16. Currently is participating in another study or has participated in an investigational study within 30 days prior to randomization.
  17. Any other serious disease or condition at Screening (or randomization) that would compromise subject safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
449 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 5 mg QD

    Drug: Azilsartan Medoxomil

  • Experimental
    Azilsartan Medoxomil 10 mg QD

    Drug: Azilsartan Medoxomil

  • Experimental
    Azilsartan Medoxomil 20 mg QD

    Drug: Azilsartan Medoxomil

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Drug: Azilsartan Medoxomil

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Drug: Azilsartan Medoxomil

  • Active comparator
    Olmesartan 20 mg QD

    Drug: Olmesartan

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: TAK-491, Edarbi

  • Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

    Also known as: Benicar

  • DrugPlacebo

    Matching placebo tablets, orally, once daily for up to 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Sitting Clinic Diastolic Blood Pressure.

    The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 8.

Secondary outcomes

  1. Change From Baseline in Sitting Clinic Systolic Blood Pressure.

    The change in sitting clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 8

  2. Change From Baseline in Standing Clinic Systolic Blood Pressure.

    The change in standing clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough standing systolic blood pressure measurements.

    Time frame: Baseline and Week 8.

  3. Change From Baseline in Standing Clinic Diastolic Blood Pressure.

    The change in standing clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough standing diastolic blood pressure measurements.

    Time frame: Baseline and Week 8.

  4. Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8.

  5. Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8.

  6. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8.

  7. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 8.

  8. Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 10 to 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.

    Time frame: Baseline and Week 8.

  9. Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 10 to 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.

    Time frame: Baseline and Week 8.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8.

  12. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8.

  13. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8.

  14. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8.

  15. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8.

  16. Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 24-36-hour mean systolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.

    Time frame: Baseline and Week 8.

  17. Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 24-36-hour mean diastolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.

    Time frame: Baseline and Week 8.

  18. Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 34-36-hour mean systolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.

    Time frame: Baseline and Week 8

  19. Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 34-36-hour mean diastolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.

    Time frame: Baseline and Week 8.

07

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 76 investigative sites in Argentina, Mexico, Peru and the United States from 16 May 2006 to 07 December 2006.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Started65656463646464
Completed63595759575752
Not completed26747712
Withdrew: Adverse event0111221
Withdrew: Protocol violation0000010
Withdrew: Lost to follow-up0100201
Withdrew: Withdrawal by subject1310134
Withdrew: Lack of efficacy1052203
Withdrew: Physician decision0000003
Withdrew: Other0101010

Outcome measures

PrimaryChange From Baseline in Sitting Clinic Diastolic Blood Pressure.

The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Clinic Diastolic Blood Pressure.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Sitting Clinic Diastolic Blood Pressure.-10.8 ± 1.08-13.1 ± 1.08-11.5 ± 1.08-13.6 ± 1.10-11.6 ± 1.08-11.0 ± 1.08-7.9 ± 1.12
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0631 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.9 · 95% CI -5.96 to 0.16
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.0008 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.3 · 95% CI -8.33 to -2.20
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.0188 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.7 · 95% CI -6.73 to -0.61
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = 0.0003 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.7 · 95% CI -8.80 to -2.63
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = 0.0177 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.7 · 95% CI -6.77 to -0.65
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.8550 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.3 · 95% CI -2.72 to 3.27
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1719 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.1 · 95% CI -5.08 to 0.91
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7469 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.5 · 95% CI -3.49 to 2.50
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.5 · 95% CI -5.55 to 0.49
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7294 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.5 · 95% CI -3.52 to 2.47
SecondaryChange From Baseline in Sitting Clinic Systolic Blood Pressure.

The change in sitting clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Sitting Clinic Systolic Blood Pressure.-11.0 ± 1.66-15.7 ± 1.66-14.7 ± 1.66-17.1 ± 1.69-13.3 ± 1.66-13.5 ± 1.66-4.9 ± 1.73
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0111 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.1 · 95% CI -10.84 to -1.41
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.8 · 95% CI -15.51 to -6.08
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.8 · 95% CI -14.53 to -5.10
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.3 · 95% CI -17.02 to -7.52
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = 0.0005 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.5 · 95% CI -13.19 to -3.76
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2768 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 2.6 · 95% CI -2.06 to 7.17
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3688 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.1 · 95% CI -6.74 to 2.51
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6293 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Median difference (final values): -1.1 · 95% CI -5.75 to 3.48
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1298 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.6 · 95% CI -8.25 to 1.06
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9315 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.2 · 95% CI -4.41 to 4.82
SecondaryChange From Baseline in Standing Clinic Systolic Blood Pressure.

The change in standing clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough standing systolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Standing Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Standing Clinic Systolic Blood Pressure.-11.4 ± 1.78-13.4 ± 1.78-16.1 ± 1.78-14.6 ± 1.81-14.0 ± 1.79-11.4 ± 1.78-3.3 ± 1.85
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0016 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.1 · 95% CI -13.17 to -3.09
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.1 · 95% CI -15.17 to -5.09
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.8 · 95% CI -17.80 to -7.72
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.3 · 95% CI -16.36 to -6.20
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.7 · 95% CI -15.75 to -5.63
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9909 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.0 · 95% CI -4.96 to 4.91
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4213 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.0 · 95% CI -6.96 to 2.92
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0646 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.7 · 95% CI -9.59 to 0.28
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2107 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.2 · 95% CI -8.15 to 1.80
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3059 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.6 · 95% CI -7.54 to 2.37
SecondaryChange From Baseline in Standing Clinic Diastolic Blood Pressure.

The change in standing clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough standing diastolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Standing Clinic Diastolic Blood Pressure.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Standing Clinic Diastolic Blood Pressure.-9.2 ± 1.17-11.0 ± 1.18-10.2 ± 1.17-11.3 ± 1.19-11.2 ± 1.18-10.8 ± 1.17-6.9 ± 1.23
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.1653 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.4 · 95% CI -5.69 to 0.98
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.0151 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.2 · 95% CI -7.50 to -0.81
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.0480 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.4 · 95% CI -6.70 to -0.03
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = 0.0098 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -7.81 to -1.08
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = 0.0113 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.3 · 95% CI -7.68 to -0.98
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3416 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.6 · 95% CI -1.68 to 4.84
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.8973 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.2 · 95% CI -3.49 to 3.06
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7292 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.6 · 95% CI -2.69 to 3.84
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7646 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.5 · 95% CI -3.79 to 2.79
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.8133 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.4 · 95% CI -3.67 to 2.88
SecondaryChange From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.5 ± 1.34-12.1 ± 1.49-11.1 ± 1.46-15.8 ± 1.57-12.4 ± 1.49-9.3 ± 1.421.0 ± 1.53
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.5 · 95% CI -12.51 to -4.51
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.1 · 95% CI -17.31 to -8.90
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.1 · 95% CI -16.27 to -7.95
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -16.8 · 95% CI -21.07 to -12.46
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.4 · 95% CI -17.58 to -9.17
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3735 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.7 · 95% CI -2.10 to 5.58
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1668 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.9 · 95% CI -6.91 to 1.20
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3629 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.9 · 95% CI -5.86 to 2.15
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0022 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.5 · 95% CI -10.67 to -2.36
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1303 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.1 · 95% CI -7.18 to 0.93
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-4.2 ± 0.90-7.3 ± 1.01-7.5 ± 0.99-9.6 ± 1.06-8.2 ± 1.01-6.2 ± 0.961.2 ± 1.03
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.4 · 95% CI -8.12 to -2.72
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.5 · 95% CI -11.33 to -5.65
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.7 · 95% CI -11.52 to -5.90
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.8 · 95% CI -13.73 to -7.91
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.5 · 95% CI -12.31 to -6.64
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1249 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 2.0 · 95% CI -0.56 to 4.61
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4542 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.0 · 95% CI -3.79 to 1.70
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3574 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.3 · 95% CI -3.97 to 1.44
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0184 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.4 · 95% CI -6.18 to -0.57
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1450 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.0 · 95% CI -4.77 to 0.70
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.2 ± 1.54-13.0 ± 1.72-11.8 ± 1.68-17.2 ± 1.80-13.0 ± 1.72-7.4 ± 1.630.6 ± 1.76
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0009 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.9 · 95% CI -12.46 to -3.26
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.6 · 95% CI -18.46 to -8.77
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.4 · 95% CI -17.21 to -7.63
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -17.9 · 95% CI -22.83 to -12.92
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.7 · 95% CI -18.52 to -8.84
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9424 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.2 · 95% CI -4.25 to 4.58
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0189 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.6 · 95% CI -10.26 to -0.93
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0612 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -9.01 to 0.21
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.9 · 95% CI -14.63 to -5.07
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0175 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.7 · 95% CI -10.33 to -1.00
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-3.6 ± 1.05-7.3 ± 1.18-8.0 ± 1.15-10.0 ± 1.23-8.7 ± 1.18-5.1 ± 1.120.6 ± 1.21
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0108 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.1 · 95% CI -7.26 to -0.95
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.9 · 95% CI -11.16 to -4.55
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.5 · 95% CI -11.82 to -5.26
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.6 · 95% CI -13.98 to -7.20
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.2 · 95% CI -12.52 to -5.90
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3060 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.6 · 95% CI -1.45 to 4.59
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1823 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.2 · 95% CI -5.37 to 1.02
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0751 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.9 · 95% CI -6.01 to 0.29
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0034 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.9 · 95% CI -8.18 to -1.64
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0306 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.5 · 95% CI -6.72 to -0.33
SecondaryChange From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 10 to 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.0 ± 1.93-11.4 ± 2.14-12.2 ± 2.12-17.4 ± 2.24-13.7 ± 2.12-7.8 ± 2.030.1 ± 2.22
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0061 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.1 · 95% CI -13.90 to -2.33
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.0002 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.5 · 95% CI -17.56 to -5.44
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.3 · 95% CI -18.34 to -6.28
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -17.5 · 95% CI -23.75 to -11.34
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.8 · 95% CI -19.86 to -7.80
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9355 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.2 · 95% CI -5.74 to 5.28
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2223 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.6 · 95% CI -9.41 to 2.20
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1328 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -10.19 to 1.35
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0016 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.7 · 95% CI -15.61 to -3.70
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0437 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.9 · 95% CI -11.70 to -0.17
SecondaryChange From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 10 to 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-3.8 ± 1.37-5.7 ± 1.52-7.4 ± 1.50-9.1 ± 1.59-8.8 ± 1.50-4.7 ± 1.440.5 ± 1.58
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0417 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.3 · 95% CI -8.39 to -0.16
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.0053 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.1 · 95% CI -10.44 to -1.84
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.0004 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.8 · 95% CI -12.12 to -3.56
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.6 · 95% CI -13.97 to -5.16
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.3 · 95% CI -13.60 to -5.03
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6372 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.9 · 95% CI -2.97 to 4.85
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6588 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.9 · 95% CI -5.05 to 3.20
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2082 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.6 · 95% CI -6.72 to 1.47
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0437 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.3 · 95% CI -8.57 to -0.12
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0495 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.1 · 95% CI -8.19 to -0.01
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-10.9 ± 1.78-14.9 ± 1.98-12.0 ± 1.93-18.8 ± 2.10-13.9 ± 1.95-13.8 ± 1.87-1.5 ± 2.08
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0007 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.4 · 95% CI -14.74 to -3.97
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.4 · 95% CI -19.02 to -7.73
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.0003 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.4 · 95% CI -16.00 to -4.83
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -17.3 · 95% CI -23.11 to -11.47
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.4 · 95% CI -18.01 to -6.78
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2594 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 2.9 · 95% CI -2.17 to 8.01
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6859 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.1 · 95% CI -6.46 to 4.26
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4898 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.9 · 95% CI -3.43 to 7.15
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0760 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.0 · 95% CI -10.55 to 0.53
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9647 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.1 · 95% CI -5.44 to 5.21
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.6 ± 1.27-11.3 ± 1.41-8.9 ± 1.38-14.0 ± 1.50-9.0 ± 1.39-9.6 ± 1.33-0.3 ± 1.48
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0002 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.3 · 95% CI -11.13 to -3.43
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.0 · 95% CI -15.01 to -6.97
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.6 · 95% CI -12.59 to -4.64
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.6 · 95% CI -17.79 to -9.50
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.7 · 95% CI -12.69 to -4.70
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2790 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 2.0 · 95% CI -1.63 to 5.62
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3772 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.7 · 95% CI -5.53 to 2.10
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7302 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.7 · 95% CI -3.11 to 4.43
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0302 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -8.31 to -0.42
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7644 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.6 · 95% CI -3.22 to 4.38
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.8 ± 1.43-13.0 ± 1.59-11.6 ± 1.56-17.3 ± 1.67-13.1 ± 1.59-8.6 ± 1.510.7 ± 1.63
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.4 · 95% CI -12.70 to -4.19
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.7 · 95% CI -18.19 to -9.24
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.2 · 95% CI -16.66 to -7.80
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -17.9 · 95% CI -22.51 to -13.35
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.7 · 95% CI -18.21 to -9.25
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6905 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.8 · 95% CI -3.26 to 4.91
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0433 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -8.76 to -0.13
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1736 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.0 · 95% CI -7.22 to 1.31
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.7 · 95% CI -13.08 to -4.23
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANOVA · p = 0.0429 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.5 · 95% CI -8.77 to -0.14
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-4.2 ± 0.96-7.7 ± 1.07-8.0 ± 1.05-10.6 ± 1.12-8.7 ± 1.07-6.0 ± 1.010.7 ± 1.09
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0009 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.9 · 95% CI -7.77 to -2.04
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.3 · 95% CI -11.33 to -5.32
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.7 · 95% CI -11.63 to -5.67
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.3 · 95% CI -14.34 to -8.18
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.4 · 95% CI -12.37 to -6.36
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2068 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.8 · 95% CI -0.98 to 4.50
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2622 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.7 · 95% CI -4.56 to 1.25
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1730 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.0 · 95% CI -4.85 to 0.88
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0025 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.6 · 95% CI -7.56 to -1.62
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0681 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.7 · 95% CI -5.60 to 0.20
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.3 ± 1.56-11.1 ± 1.73-10.4 ± 1.69-13.1 ± 1.83-11.4 ± 1.72-10.6 ± 1.631.3 ± 1.81
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0004 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.6 · 95% CI -13.28 to -3.87
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.3 · 95% CI -17.26 to -7.42
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.6 · 95% CI -16.51 to -6.78
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -14.3 · 95% CI -19.38 to -9.25
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.6 · 95% CI -17.53 to -7.70
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1479 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 3.3 · 95% CI -1.17 to 7.72
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.8382 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.5 · 95% CI -5.16 to 4.19
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.9317 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.2 · 95% CI -4.42 to 4.82
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3169 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.5 · 95% CI -7.29 to 2.37
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.7488 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.8 · 95% CI -5.44 to 3.91
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-4.8 ± 1.09-7.4 ± 1.21-6.8 ± 1.18-8.5 ± 1.29-7.8 ± 1.21-6.1 ± 1.151.9 ± 1.27
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.7 · 95% CI -9.98 to -3.40
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.3 · 95% CI -12.76 to -5.86
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.6 · 95% CI -12.05 to -5.22
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.4 · 95% CI -13.92 to -6.79
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.7 · 95% CI -13.11 to -6.20
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4188 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 1.3 · 95% CI -1.83 to 4.40
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4255 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.3 · 95% CI -4.62 to 1.95
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.6869 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.7 · 95% CI -3.91 to 2.58
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1678 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.4 · 95% CI -5.77 to 1.01
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3132 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.7 · 95% CI -4.96 to 1.60
SecondaryChange From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-36-hour mean systolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.4 ± 1.51-12.0 ± 1.64-11.5 ± 1.62-14.6 ± 1.72-13.5 ± 1.62-8.9 ± 1.56-1.4 ± 1.70
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0005 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.0 · 95% CI -12.48 to -3.52
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.6 · 95% CI -15.24 to -5.93
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.1 · 95% CI -14.70 to -5.44
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.2 · 95% CI -17.95 to -8.42
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.1 · 95% CI -16.74 to -7.48
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.8103 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -0.5 · 95% CI -4.79 to 3.75
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1702 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.1 · 95% CI -7.57 to 1.34
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2504 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.6 · 95% CI -7.02 to 1.84
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0144 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.7 · 95% CI -10.28 to -1.14
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0402 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.6 · 95% CI -9.06 to -0.21
SecondaryChange From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-36-hour mean diastolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-5.6 ± 1.07-7.9 ± 1.17-8.6 ± 1.15-9.5 ± 1.22-7.9 ± 1.15-6.5 ± 1.11-0.4 ± 1.21
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0014 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.2 · 95% CI -8.41 to -2.04
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.5 · 95% CI -10.82 to -4.22
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.2 · 95% CI -11.51 to -4.93
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.1 · 95% CI -12.49 to -5.72
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = < 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.6 · 95% CI -10.87 to -4.30
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.5519 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): 0.9 · 95% CI -2.11 to 3.95
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3938 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.4 · 95% CI -4.54 to 1.79
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1949 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.1 · 95% CI -5.21 to 1.07
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0732 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.0 · 95% CI -6.21 to 0.28
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3669 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.4 · 95% CI -4.59 to 1.70
SecondaryChange From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 34-36-hour mean systolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-10.1 ± 1.96-11.2 ± 2.10-9.8 ± 2.15-13.5 ± 2.39-11.8 ± 2.12-7.4 ± 2.12-0.9 ± 2.17
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.0019 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.2 · 95% CI -14.94 to -3.41
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.0008 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.2 · 95% CI -16.15 to -4.26
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.0040 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.9 · 95% CI -14.88 to -2.85
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = 0.0001 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.6 · 95% CI -18.96 to -6.22
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = 0.0004 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.9 · 95% CI -16.85 to -4.89
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3499 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.7 · 95% CI -8.39 to 2.98
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2115 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.7 · 95% CI -9.61 to 2.14
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4279 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.4 · 95% CI -8.34 to 3.54
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.0566 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.1 · 95% CI -12.41 to 0.17
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1435 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.4 · 95% CI -10.30 to 1.50
SecondaryChange From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 34-36-hour mean diastolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-0.4 ± 1.160.3 ± 1.260.9 ± 1.240.4 ± 1.40-0.6 ± 1.341.9 ± 1.352.4 ± 1.31
Statistical analysis
  • Azilsartan Medoxomil 5 mg QD vs Placebo QD · ANCOVA · p = 0.1162 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.7 · 95% CI -6.16 to 0.68
  • Azilsartan Medoxomil 10 mg QD vs Placebo QD · ANCOVA · p = 0.2494 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.1 · 95% CI -5.69 to 1.48
  • Azilsartan Medoxomil 20 mg QD vs Placebo QD · ANCOVA · p = 0.4247 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.4 · 95% CI -5.01 to 2.12
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = 0.3007 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.0 · 95% CI -5.79 to 1.80
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = 0.1195 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -3.0 · 95% CI -6.67 to 0.77
  • Azilsartan Medoxomil 5 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.2032 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.3 · 95% CI -5.76 to 1.23
  • Azilsartan Medoxomil 10 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.3787 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.6 · 95% CI -5.27 to 2.01
  • Azilsartan Medoxomil 20 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.5967 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.0 · 95% CI -4.59 to 2.64
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.4345 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -1.5 · 95% CI -5.36 to 2.31
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 20 mg QD · ANCOVA · p = 0.1954 (P-value from analysis of covariance with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -2.5 · 95% CI -6.24 to 1.28

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 5 mg QD—1/65 (1.5%)7/65 (10.8%)
Azilsartan Medoxomil 10 mg QD—1/64 (1.6%)7/64 (10.9%)
Azilsartan Medoxomil 20 mg QD—0/64 (0%)13/64 (20.3%)
Azilsartan Medoxomil 40 mg QD—1/62 (1.6%)8/62 (12.9%)
Azilsartan Medoxomil 80 mg QD—0/64 (0%)7/64 (10.9%)
Olmesartan 20 mg QD—1/63 (1.6%)7/63 (11.1%)
Placebo QD—1/63 (1.6%)7/63 (11.1%)
Most frequent serious events
Most frequent serious events
EventAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
Oesophageal SpasmGastrointestinal disorders0/650/640/641/620/640/630/63
Cardiac ArrestCardiac disorders0/650/640/640/620/641/630/63
Hypertensive Heart DiseaseCardiac disorders0/650/640/640/620/641/630/63
Myocardial InfarctionCardiac disorders0/650/640/640/620/640/631/63
Gastrointestinal HaemorrhageGastrointestinal disorders0/650/640/640/620/640/631/63
HeadacheNervous system disorders0/651/640/640/620/640/630/63
HydrocephalusNervous system disorders0/651/640/640/620/640/630/63
Wound InfectionInfections and infestations1/650/640/640/620/640/630/63
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QD
HeadacheNervous system disorders2/651/647/643/623/645/633/63
NasopharyngitisInfections and infestations0/653/643/641/623/641/634/63
DizzinessNervous system disorders1/653/644/642/621/641/632/63
Upper respiratory tract infectionInfections and infestations4/650/640/642/620/640/630/63

Baseline characteristics

Age Categorical
Age Categorical(participants)Azilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QDTotal
<45 years12510912101169
Between 45 and 64 years45524643414636309
≥65 years868101171464
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 5 mg QDAzilsartan Medoxomil 10 mg QDAzilsartan Medoxomil 20 mg QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDOlmesartan 20 mg QDPlacebo QDTotal
Female29323033283432218
Male36313429362929224
08

Study locations

54 sites
  • Huntsville, Alabama, United States
  • Ozark, Alabama, United States
  • Mesa, Arizona, United States
  • Little Rock, Arkansas, United States
  • Carmichael, California, United States
  • Long Beach, California, United States
  • San Diego, California, United States
  • Tustin, California, United States
  • Denver, Colorado, United States
  • Stamford, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Pembroke Pines, Florida, United States
  • Pinellas Park, Florida, United States
  • Atlanta, Georgia, United States
  • Evansville, Indiana, United States
  • Shawnee Mission, Kansas, United States
  • Auburn, Maine, United States
  • Trenton, New Jersey, United States
  • Binghamtom, New York, United States
  • Rochester, New York, United States
  • Burlington, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Concord, North Carolina, United States
  • Hickory, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Oklahoma, Oklahoma, United States
  • Anderson, South Carolina, United States
  • Mt. Pleasant, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Bristol, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Euless, Texas, United States
  • North Richland Hills, Texas, United States
  • San Antonio, Texas, United States
  • Lakewood, Washington, United States
  • Renton, Washington, United States
  • Madison, Wisconsin, United States
  • BA, Argentina
  • Cordoba, Argentina
  • Ushuaia, Argentina
  • Guadalajara, Jal, Mexico
  • Mexico, D.F., Mexico
  • Monterrey Nuevo Leon, Mexico
  • Morelia, Michoacan, Mexico
  • Lima, Peru
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2006
First posted
Aug 9, 2006
Start
May 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00362115
Lead sponsor
Takeda
First posted
Aug 9, 2006
Start date
May 2006
Primary completion
Dec 2006
Completion
Dec 2006
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion